Bibliography
- CESANO A, GAYKO U: CD22 as a target of passive immunotherapy. Semin. Oncol (2003) 30(2):253–257.
- LEONARD JP, COLEMAN M, KETAS JC et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. I Clin. Oncol (2003) 21:3051–3059.
- LYNCH DH, YANG XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol (2002) 29\(Suppl. 4):47–50.
- SHINKAWA T, NAKAMURA K, YAMANE N et al.: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. (2003) 278(5):3466–3473.
- HURWITZ H, FEHRENBACHER L, CARTWRIGHT T et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol (2003) (Abstract 3646).
- DAVIS PD, DOUGHERTY GJ, BLAKEY DC et al: ZD6126: A novel vascular targeting agent that causes selective destruction of tumor vasculature. Cancer Res. (2002) 62(24):7247–7253.
- •Initial paper describing activity of ZD6126 and the rationale for selective destruction of tumour vasculature.
- BLAKEY DC, WESTWOOD FR, WALKER M et al.: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Gin. Cancer Res. (2002) 8(6):1974–1983.
- SIEMANN DW, ROJIANI AM: Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int. J. Radiat. Oncol Biol. Phys. (2002) 54(5):1512–1517.
- •Excellent paper demonstrating the value of combining vascular-targeting agents with certain conventional cytotoxic drugs.
- WEDGE SR, KENDREW J, OGILVIE DJ et al.: Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced antitumor response. Proc. Am. Assoc. Cancer Res. (2002) 43:1081.
- GALBRAITH SM, MAXWELL, RJ, LODGE MA et al.: Combretastin A4 Phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol (2003) 21(15):2831–2842.
- •Key paper highlighting the value of imaging for monitoring vascular-targeting agent activity preclinically and in the clinic.
- HILL SA, TOZER GM, PETTIT GR, CHAPLIN DJ: Preclinical evaluation of the antitumour activity of the novel vascular targeting agent ad 4503. Anti-Cancer Res. (2002) 22(3):1453–1458.
- ADAMS J: The proteasome: structure, function, and role in the cell. Cancer Treat. Rev (2003) 29\(Suppl. 1):3–9.
- RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348(26):2609–2617.
- WHITEHEAD CM, RATTNER JB: Expanding the role of HsEg5 within the mitotic and post-mitotic phases of the cell cycle../. Cell. Sci. (1998) 111(17):2551–2561.
- HOOPER JD, CLEMENTS JA, QUIGLEY JP, ANTALIS TM: Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. (2001) 276(2):857–860.